Isomorphic Labs, AI 신약 개발을 위해 21억 달러 조달
alphabet 소유의 isomorphic labs는 thrive capital이 주도한 시리즈 B 펀딩에서 21억 달러를 확보해 ai로 생성한 신약 후보물질의 임상시험 진입을 추진합니다.
alphabet subsidiary isomorphic labs secured $2.1 billion in series b funding co-led by thrive capital to scale its ai-driven drug discovery platform. the capital injection aims to advance the company's pipeline of therapeutics into clinical trials and support global hiring efforts for its isodde ai system. founder demis hassabis stated the technology has proven itself and focuses on the mission to solve all disease. this funding reinforces the viability of ai in biotech, bolstering existing collaborations with major pharmaceutical firms like novartis, lilly, and johnson & johnson.